Version history

{
  "session_id": "sess_SDA-BIOMNI-CLINICAL-b7a71edd",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "mini-max",
  "action": "support",
  "content": "\n\n# Feasibility Assessment: AD Pipeline Hypotheses\n\n## Surviving Hypotheses After Critique\n\n**H1 (Pipeline Distortion)** is an *observation*, not a therapeutic hypothesis. It survives as framing but offers no actionable target. Move to context-setting.\n\n**H2, H3, and H4** remain viable with modifications. Below are targeted feasibility assessments.\n\n---\n\n## Hypothesis 2: Microglial Targets (TREM2, PLCG2, INPP5D)\n\n### Druggability & Therapeutic Potential\n\n| Target | Modality | Feasibility | Notes |\n|--------|----------|-------------|-------|\n| **TREM2** | Agonistic antibodies, small molecule activators | **Moderate-High** | Genetic validation is strong; BBB penetration is the primary barrier |\n| **PLCG2** | Positive allosteric modulators | **Moderate** | P522R variant provides clear pharmacodynamic hypothesis; no CNS-penetrant leads yet |\n| **INPP5D (SHIP1)** | Inhibitors (existing oncology compounds) | **Low-Moderate** | BBB penetration demonstrated in CNS oncology; systemic toxicity concerns |\n\n**Realistic potential:** Modest disease modification by shifting microglia toward Aβ clearance phenotype. Monotherapy unlikely to match anti-amyloid efficacy; more plausible as combination component.\n\n### Existing Compounds/Trials\n\n- **TREM2 agonists:** No clinical-stage programs as of 2024. Preclinical: AL002 (Alector), but this was discontinued after Phase II failure in 2022. Slightly earlier-stage: antibodies in academic settings (University of California, Alzheimer's Research UK funded programs).\n- **PLCG2 modulators:** No disclosed clinical programs. Fragment-based discovery has identified initial hit series.\n- **INPP5D inhibitors:** Tenalisib (RBx-05959) in oncology trials; no AD-specific development.\n\n### Development Cost & Timeline\n\n- **Cost:** $200-400M to Phase II (BBB-permeable biologics/small molecules)\n- **Timeline:** 7-10 years to Phase II completion\n- **Major cost driver:** TREM2-targeting antibodies require IV delivery; blood-brain barrier penetration often requires active transport engineering\n\n### Safety Concerns\n\n- **TREM2:** Overactivation may dysregulate microglial homeostasis; theoretical risk of cytokine release or impaired surveillance\n- **PLCG2:** Constitutive activity may promote inflammation; isoform selectivity critical\n- **INPP5D:** SHIP1 inhibition in oncology shows GI toxicity, pneumonitis risk; CNS exposure may compound these\n\n---\n\n## Hypothesis 3: Mitochondrial & Proteostatic Mechanisms\n\n### Druggability & Therapeutic Potential\n\n| Target | Modality | Feasibility | Notes |\n|--------|----------|-------------|-------|\n| **NAD⁺ augmentation** | NR, NMN, nicotinamide riboside | **High** | Oral bioavailability established; BBB penetration moderate |\n| **SIRT1/3 activators** | Small molecule activators | **Moderate** | Selective activation is difficult; resveratrol failed clinically |\n| **Autophagy modulators** | mTOR inhibitors (rapamycin analogs), TFEB activators | **Moderate** | Non-selective mTOR inhibition has tolerability issues |\n\n**Realistic potential:** Neuroprotective maintenance rather than disease modification. Best positioned as **preventive** or combinatorial strategy. NAD⁺ augmentation is the most translation-ready.\n\n### Existing Compounds/Trials\n\n- **NAD⁺ boosters:** Nicotinamide riboside (Tru NIAGEN) in multiple investigator-initiated AD trials; NMN in early human studies in Japan. No sponsor-initiated Phase II efficacy trials.\n- **SIRT1 activators:** SRT2104 (葛兰素史克) completed Phase II in ulcerative colitis; no AD trials.\n- **Autophagy modulation:** Rapamycin in aging trials; no AD-specific development despite strong preclinical data.\n\n### Development Cost & Timeline\n\n- **Cost:** $50-150M to Phase II for repurposed agents (NR, NMN); $300M+ for novel autophagy modulators\n- **Timeline:** 4-6 years for NAD⁺ augmentation (using existing compounds); 8-12 years for selective SIRT1/3 activators\n- **Advantage:** Existing tox profiles and human safety data accelerate development\n\n### Safety Concerns\n\n- **NAD⁺ augmentation:** Generally well-tolerated; theoretical concerns about overactivation of NAD⁺-consuming enzymes (PARPs, CD38) in cancer patients\n- **SIRT1 activators:** Cardiovascular effects possible (SIRT1 affects eNOS); narrow therapeutic window\n- **Autophagy modulators:** Immunosuppression risk (mTOR inhibitors); metabolic effects\n\n---\n\n## Hypothesis 4: Combinatorial & Preventive Trials\n\nThis is a **trial design hypothesis**, not a drug target. Assess feasibility of the proposed strategies:\n\n### Combination Trials\n\n**Feasibility: Moderate**\n- Anti-amyloid + anti-inflammatory combinations are conceptually straightforward\n- Regulatory pathway exists (parallel development) but requires two active compounds\n- Example models: Cancer immunotherapy combinations; cardiovascular polypharmacy\n\n**Barriers:**\n- Two-company partnerships are difficult to negotiate\n- Liability allocation for adverse events\n- Dosing complexity (drug-drug interactions poorly studied in AD)\n\n### Preventive Trials\n\n**Feasibility: Low-Moder",
  "tokens_used": "1257"
}